MedAdvisor Limited (AU:MDR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MedAdvisor Limited anticipates a notable shift in revenue from the first half to the second half of FY25 due to lower-than-expected flu vaccination rates in the US. While the company’s Australian operations remain stable, MedAdvisor is counting on a diverse and strong second-half pipeline in the US to boost revenue. The company remains optimistic about a record-breaking second half, attributing this to strategic diversification efforts.
For further insights into AU:MDR stock, check out TipRanks’ Stock Analysis page.